Related Experiment Video
Updated: Mar 23, 2026
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Proof of principle for bevacizumab activity in desmoid-type fibromatosis
Viktor Grünwald1, Florian Länger2, H J Raatschen3
1Clinic for Hematology, Hemostasis, Oncology and Stemcelltransplantation, Medical School Hannover, Carl-Neuberg-Str. 1, Hannover, Germany.
Background:
Desmoid-type fibromatosis (DF) is a rare disease, which often occurs in young adults. Medical treatment is an important option in the treatment algorithm of DF. Different chemotherapeutic regimens showed clinical activity in DF, but overall treatment tolerability remains poor for this patient cohort. Novel approaches investigated tyrosine kinase inhibitors in DF, but tolerability remained an issue.
Case Presentation:
We treated a patient with progressive DF after failure of chemotherapy for 1 year with singe agent bevacizumab. He achieved a symptomatic and radiologic response while attainning excellent tolerability.
Conclusions:
This is the first report on single agent bevacizumab in DF, which showed both, good tolerability and efficacy in our patient, thereby warranting future trials in DF.
Insights
Single agent bevacizumab shows promise for treating desmoid-type fibromatosis (DF). This rare tumor treatment demonstrated good tolerability and efficacy in a patient with progressive DF.
Area of Science:
- Oncology
- Medical research
Background:
- Desmoid-type fibromatosis (DF) is a rare neoplasm affecting young adults.
- Current treatments for DF, including chemotherapy and tyrosine kinase inhibitors, have limited efficacy and poor tolerability.
- Novel therapeutic strategies are needed for effective DF management.
Observation:
- A patient with progressive desmoid-type fibromatosis (DF) received single-agent bevacizumab therapy.
- The patient had previously undergone unsuccessful chemotherapy treatments for DF.
- Bevacizumab treatment was administered for one year.
Findings:
- Single-agent bevacizumab demonstrated significant symptomatic and radiologic response in the patient with DF.
- The treatment was well-tolerated, with no significant adverse events reported.
- This represents the first report of bevacizumab monotherapy in DF.
Implications:
- Bevacizumab monotherapy presents a potential new treatment option for desmoid-type fibromatosis (DF).
- Further clinical trials are warranted to evaluate the efficacy and safety of bevacizumab in a larger DF patient cohort.
- This finding could lead to improved treatment outcomes and patient tolerability in DF management.
